Rare disease drug developers struggle to survive in a biopharma investment market that prioritizes large patient populations.
According to an official press release, ZETA DIVISION is set to compete in the APAC North region, starting with the 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results